TEGSEDI (inotersen)

SELF ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Patients must meet the following criteria for the indication(s) above:

  • Patient is 18 years of age or older, AND
  • Prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis, AND
  • Patient has a diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR) as confirmed by chart note documentation, AND
  • Patient has a transthyretin (TTR) mutation as confirmed by genetic testing, AND
  • Patient has symptomatic peripheral neuropathy (e.g. reduced motor strength/coordination, impaired sensation [e.g. pain, temperature, vibration, touch]) , AND
  • Patient has tried and failed at least one systemic agent for polyneuropathy from the following classes:
    • Gabapentin-type product (e.g. Gabapentin, Lyrica®), OR 
    • Tricyclic antidepressant (e.g. Amitriptyline, Nortriptyline), AND
  • Patient has not had a liver transplant, AND
  • Patient does not have any of the following contraindications to use: 
    • Platelet count less than 100 x 109/L 
    • History of acute glomerulonephritis caused by Tegsedi™

Dosing: 

  • 284mg subcutaneously once weekly

Approval: 

  • 1 year

Last review date: September 3, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone